Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $2.7 million.

  • Puma Biotechnology's Depreciation & Amortization (CF) fell 542.04% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 388.87%. This contributed to the annual value of $11.5 million for FY2024, which is 4.34% up from last year.
  • As of Q3 2025, Puma Biotechnology's Depreciation & Amortization (CF) stood at $2.7 million, which was down 542.04% from $2.8 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Depreciation & Amortization (CF) high stood at $3.0 million for Q4 2021, and its period low was $2.4 million during Q3 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $2.9 million (2023), whereas its average is $2.8 million.
  • In the last 5 years, Puma Biotechnology's Depreciation & Amortization (CF) surged by 5401.88% in 2021 and then tumbled by 1762.93% in 2022.
  • Puma Biotechnology's Depreciation & Amortization (CF) (Quarter) stood at $3.0 million in 2021, then dropped by 17.63% to $2.5 million in 2022, then increased by 17.77% to $2.9 million in 2023, then decreased by 1.66% to $2.8 million in 2024, then fell by 4.19% to $2.7 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.7 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.8 million for Q1 2025.